# SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

> **NCT04201496** · PHASE1 · COMPLETED · sponsor: **Ananda Basu, MD** · enrollment: 34 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **COMBINATION_PRODUCT:** Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
- **COMBINATION_PRODUCT:** Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
- **DEVICE:** No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
- **DEVICE:** No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks

## Key facts

- **NCT ID:** NCT04201496
- **Lead sponsor:** Ananda Basu, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-24
- **Primary completion:** 2021-09-07
- **Final completion:** 2021-09-07
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-08-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04201496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04201496, "SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04201496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*